Citation Impact
Citing Papers
Diagnosis and management of acute myeloid leukemia in adults: recommendations from an international expert panel, on behalf of the European LeukemiaNet
2009 Standout
Trastuzumab in combination with chemotherapy versus chemotherapy alone for treatment of HER2-positive advanced gastric or gastro-oesophageal junction cancer (ToGA): a phase 3, open-label, randomised controlled trial
2010 Standout
Gastric cancer
2016 Standout
Resection margins, extrapleural nodal status, and cell type determine postoperative long-term survival in trimodality therapy of malignant pleural mesothelioma: Results in 183 patients
1999 Standout
Perioperative Chemotherapy versus Surgery Alone for Resectable Gastroesophageal Cancer
2006 Standout
Unravelling mechanisms of cisplatin sensitivity and resistance in testicular cancer
2013
Patient-Derived Xenograft Models: An Emerging Platform for Translational Cancer Research
2014 Standout
A case report of malignant pleural mesothelioma with long-term disease control after chemotherapy
1991
Cancer nanomedicine: progress, challenges and opportunities
2016 Standout
Clonogenic assay with established human tumour xenografts
2004
Vascular endothelial growth factor (VEGF) mRNA expression in human tumor models of different histologies
1995
Renal-Cell Carcinoma
1996 Standout
Treatment of unresectable cholangiocarcinoma
2012
Lobaplatin in advanced urothelial tract tumors
1997
Preclinical antitumour activity and animal toxicology studies of rhizoxin, a novel tubulin-interacting agent
1992
Enhancement of the antiproliferative activity of cis‐diamminedichloroplatinum(II) by quercetin
1990
Chemotherapy in malignant mesothelioma: a review
1991
Prognostic factors of malignant mesothelioma of the pleura
1993
Acute myeloid leukaemia
2006
Management of Gallbladder Cancer
2010
Integrated preclinical and clinical development of mTOR inhibitors in pancreatic cancer
2010
Tubulin as a target for anticancer drugs: Agents which interact with the mitotic spindle
1998 Standout
Natural products to drugs: natural product-derived compounds in clinical trials
2008 Standout
The biochemistry and medical significance of the flavonoids
2002 Standout
Cycloplatam: A novel platinum compound exhibiting a different spectrum of anti-tumour activity to cisplatin
1995
Randomized phase II trial of cisplatin with mitomycin or doxorubicin for malignant mesothelioma by the Cancer and Leukemia Group B.
1993
Epirubicin
1993
Structure-antitumor activity relationship of semi-synthetic spicamycin analogues.
1993
Factors Predictive of Survival Among 337 Patients With Mesothelioma Treated Between 1984 and 1994 by the Cancer and Leukemia Group B
1998
High liposomal doxorubicin tumour tissue distribution, as determined by radiopharmaceutical labelling with 99mTc-LD, is associated with the response and survival of patients with unresectable pleural mesothelioma treated with a combination of liposomal doxorubicin and cisplatin
2014
Guidelines for the diagnosis and management of intrahepatic cholangiocarcinoma
2014 Standout
Antitumor activity of SPM VIII, a derivative of the nucleoside antibiotic spicamycin, against human tumor xenografts.
1994
Gastric cancer
2020 Standout
Management of malignant pleural effusions
2001 Standout
Cisplatin: The first metal based anticancer drug
2019 Standout
Gastric cancer: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up
2010 Standout
Gallbladder cancer: epidemiology and outcome
2014 Standout
A Clinical Screening Cooperative Group phase II evaluation of lobaplatin (ASTA D-19466) in advanced head and neck cancer
1995
Preclinical phase II studies in human tumor lines: A European multicenter study
1988
The status of platinum anticancer drugs in the clinic and in clinical trials
2010 Standout
Advances in Malignant Mesothelioma
2005 Standout
S-1 plus cisplatin versus S-1 alone for first-line treatment of advanced gastric cancer (SPIRITS trial): a phase III trial
2008 Standout
Chemotherapy of gastric cancer
1988
The Next Generation of Platinum Drugs: Targeted Pt(II) Agents, Nanoparticle Delivery, and Pt(IV) Prodrugs
2016 Standout
Anthracyclines suppress pheochromocytoma cell characteristics, including metastasis, through inhibition of the hypoxia signaling pathway
2017 StandoutNobel
Metalle in der Medizin
1999
Phase III Study of Pemetrexed in Combination With Cisplatin Versus Cisplatin Alone in Patients With Malignant Pleural Mesothelioma
2003 Standout
Lobaplatin: a new antitumour platinum drug
2001
Current Status of Platinum-Based Antitumor Drugs
1999 Standout
Acute Myeloid Leukemia and Myelodysplastic Syndromes in Older Patients
2007
Current status of trans-platinum compounds in cancer therapy
2001
The antitumor activities of flavonoids.
2005 Standout
Additions to Metal-Activated Organonitriles
2002 Standout
Asymmetric Catalysis by Architectural and Functional Molecular Engineering: Practical Chemo- and Stereoselective Hydrogenation of Ketones
2001 StandoutNobel
Pharmacokinetics and pharmacodynamics of lobaplatin (D-19466) in patients with advanced solid tumors, including patients with impaired renal of liver function.
1999
Chemotherapy for advanced gastric cancer
2017 Standout
Role of chemotherapy for advanced/recurrent gastric cancer: An individual-patient-data meta-analysis
2013
Photoactivated platinum-based anticancer drugs
2018
The Effects of Plant Flavonoids on Mammalian Cells:Implications for Inflammation, Heart Disease, and Cancer
2000 Standout
Phase II study with the combination etoposide, doxorubicin, and cisplatin in advanced measurable gastric cancer.
1989
Asymmetrische Katalyse mit hinsichtlich Struktur und Funktion gezielt entworfenen Molekülen: die chemo- und stereoselektive Hydrierung von Ketonen
2001 StandoutNobel
Clinical predictive value of the in vitro cell line, human xenograft, and mouse allograft preclinical cancer models.
2003 Standout
Best Supportive Care Compared With Chemotherapy for Unresectable Gall Bladder Cancer: A Randomized Controlled Study
2010
Anthraquinones As Pharmacological Tools and Drugs
2016 Standout
Genetics of Biliary Tract Cancers and Emerging Targeted Therapies
2010
Works of H. Henß being referenced
Phase III study of 5-FU and carmustine versus 5-FU, carmustine, and doxorubicin in advanced gastric cancer.
1986
Outpatient chemotherapy with gemcitabine and oxaliplatin in patients with biliary tract cancer
2006
Colony assay with human tumor xenografts, murine tumors and human bone marrow. Potential for anticancer drug development
1987
Preclinical phase II study of ifosfamide in human tumour xenografts in vivo
1990
[Prognostic factors in diffuse malignant mesothelioma of the pleura].
1989
Phase II Clinical Trial of Lobaplatin (D-19466) in Pretreated Patients with Small-Cell Lung Cancer
1996
Development of Three Human Small Cell Lung Cancer Models in Nude Mice
1985
5-fluorouracil, 4-epidoxorubicin, and mitomycin C (FEM) for advanced gastric carcinoma. A phase II trial
1986
The clonogenic assay with human tumor xenografts: Evaluation, predictive value and application for drug screening
1990
Phase I Clinical Trial of Lobaplatin (D-19466) after Intravenous Bolus Injection
1994
5-Fluorouracil, 4-Epidoxorubicin, and Mitomycin C (FEM) Combination Chemotherapy for Advanced Gastric Carcinoma. A Phase-II Trial by the “Chemotherapiegruppe Gastrointestinaler Tumoren (CGT)”
1987
Treatment of advanced pleuramesothelioma with Cis-platinum and Adriamycin
1986
Phase-II Study with the Combination of Cisplatin and Doxorubicin in Advanced Malignant Mesothelioma of the Pleura
1988
Continued Low-Dose Decitabine (DAC) Is an Active First-Line Treatment of Older AML Patients: First Results of a Multicenter Phase II Study.
2005
Prospektive randomisierte Studie beim fortgeschrittenen Magenkarzinom: Vergleich der Kombination von 5-Fluorouracil und Carmustin ohne und mit Adriamycin
2008